Slide 1: Welcome to the 3Q22 Webinar
Welcome to the 3Q22 Webinar modulight
Slide 2: Today's agenda
Today’s agenda • Q3 highlights • Project pipeline development • Progress with investments Update picture • Strategy • Q&A Carolina Urologic Research Center, Myrtle Beach, SC (Sep-22) 2
Slide 3: Strategy execution continued, significant progress in the R&D project pipeline
Strategy execution continued, significant progress in the R&D project pipeline • Continued execution of the growth strategy and investments in increasing production capacity • Significant progress in the R&D project pipeline and opportunities to accelerate the pay per treatment cloud strategy in the
Slide 4: Financial highlights July–September 2022
Financial highlights July–September 2022 • Revenue -42% yoy mainly Revenue EBITDA EBIT due to uncertainty in the business environment EUR EUR EUR • Lower profitability due to lower revenue 1,232 -1,342 -1,812 • Costs increased due to thousand growth strategy thousand thousand implementation -109% of
Slide 5: Key figures
Key figures Key figures1) (EUR 1,000 unless otherwise noted) 7-9/2022 7-9/2021 1-9/2022 1-9/2021 1-12/20212) Revenue 1,232 2,137 3,331 6,697 9,071 EBITDA -1,342 1,025 -3,936 4,183 461 EBITDA-% -108.9% 48.0% -118.2% 62.5% 5.1% Operating result (EBIT) -1,812 716 -5,292 3,321 - 753 Operating result (EB
Slide 6: Solid product development pipeline
Solid product development pipeline • 26 projects Number of projects with commercialization potential • Opportunity to accelerate 30 cloud strategy (pay per treatment business model) 25 from recent talks in Chicago and elsewhere in US but also 20 European customers 15 • One new project initiated in d
Slide 7: A typical project
A typical project CASE EXAMPLE: Generic Modulight customer project flow Customer contacts Modulight 6 – 24 months 3 – 5 years 5 – 10 years Sales cycles Typical projects Project plans are often ambitious - New cancer GTM phase – vary – often start with early delays are common due to many therapies Mo
Slide 8: Revenue model
Revenue model The objective is revenue, based on the Customized R&D projects based on the Best Efforts principle, share of pharmaceutical or treatment without revenue risk for Modulight fees, or the utilization rate of industrial applications. Predictability of Modulight’s revenue is improving Curre
Slide 9: Modulight's customer base
Modulight’s customer base Customer ownership 30 25 • 12% are research companies 20 • 31% are privately owned 15 • 58% of customers are listed 10 companies • 62% are established companies 5 • 27% have over 1bn revenue 0 3Q21 4Q21 1Q22 2Q22 3Q22 Hospitals & Research Private company Listed company 9
Slide 10: Product development pipeline progressing
Product development pipeline progressing Customer: Major NYSE listed Customer: Publicly listed US Customer: Publicly listed US medical pharmaceutical company pharmaceutical company device company Indication: Ophthalmology Indication: Bladder cancer Indication: Dermatology In recent meetings with cus
Slide 11: Progress with investments
Progress with investments Epitaxial wafer ❑ Investments starting to show operational benefits: ❖ Further differentiation ❖ Expanded offering ❖ Increased productivity ❖ Higher capacity ❑ Record number of CAPEX tool investments on- going & several installation teams from Japan and elsewhere at Modulig
Slide 12: Growth strategy execution
Growth strategy execution Go-to-market strategy update progressing well, to be announced later this year Increasing Geographical Expanding the Opportunities for Continuous production expansion product range expansion in the investments in capacity other indications field of cloud software and laser
Slide 13: Outlook
Outlook Modulight has not issued a guidance for revenue or profitability in 2022. As the company’s customer projects are still distributed across varying early stages of development, and predicting developments in the market remains challenging, it is difficult to forecast performance in 2022. Howev
Slide 14: Summary
Summary • Significant progress in the R&D project pipeline and opportunities to accelerate the pay per treatment cloud strategy in the short term • Product development pipeline remained solid at 26 projects • Customer development projects still affected by COVID-19 related delays and shortages in co
Slide 15: Thank you! Questions?
Thank you! Questions? LEARN MORE AND FOLLOW US IN LINKEDIN, TWITTER, FACEBOOK, YOUTUBE AND INSTAGRAM: 15